Vanzacaftor negative in Ames, in vitro TK6 micronucleus and in vivo rat micronucleus assays
“Vanzacaftor was negative for genotoxicity in the following assays: Ames test for bacterial gene variant, in vitro micronucleus assay in TK6 cells, and in vivo rat micronucleus assay.”
Vanzacaftor: 6-month rasH2 mouse negative up to 30 mg/kg/day; 2-year rat study also conducted
“In the case of VNZ, the studies consisted of a 6-month Tg.rasH2 transgenic mouse carcinogenicity study and a 2-year rat carcinogenicity study. VNZ did not demonstrate a carcinogenic potential at the doses evaluated in the Tg.rasH2 mouse up to 30mg/kg/day.”
Vanzacaftor rat and rabbit EFD: no adverse developmental effects up to 30x (rat) and 22x (rabbit) MRHD exposure
“In animal embryo fetal development (EFD) studies, oral administration of vanzacaftor to pregnant rats and rabbits during organogenesis demonstrated no adverse developmental effects at doses that produced maternal exposures up to approximately 30 times the exposure at the maximum recommended human dose (MRHD) in rats and 22 times the MRHD in rabbits.”
“VNZ inhibited hERG current with an IC50 of 0.7 μM, which provides a ~3800-fold margin of exposure over the clinical concentration (free Cmax). Effects of VNZ on the cardiovascular system was assessed in telemetered male dogs.”
Not genotoxic overall: Ames negative; in vitro chromosome aberration positive without (not with) metabolic activation; rat micronucleus and comet negative